Mitochondrial Donation
Senate Committee recommends pathway to legislative change so babies in Australia do not suffer with mitochondrial disease. Read more
Read Tom's story
Tom was four when he began experiencing symptoms of Leigh syndrome. Now 31, Tom is thriving and giving back to the community to inspire those living with mito. Read more
AGHA-Mito Foundation Genetic Testing Partnership
A revolutionary genomics study providing access to accurate diagnoses for those suspected of having mito Read more
Do you have mito?
Currently, no one has a complete understanding of the number of people with mito, what type of mito they may have, who they are and how to contact them. The Mito Registry is building that picture... Read more
Looking for support or information?
Connect with others who are affected by mito via our Support Groups, Support Network or Teleconferences. Read more
Mito 4 Kids
A school education program about mitochondrial disease. Read more

Next

Previous

About Mito Foundation

Research Update
New research is taking place bringing us closer to effective treatments and cures for mito.

First IVF Baby Turns 40
Happy 40 birthday Louise Brown! Louise’s birth was ground breaking and provided hope to millions of couples.

New research into nucleoside therapy aims to develop a treatment for deadly mitochondrial disease
Read our media release about a pioneering project we are co-funding with The Lily Foundation.

For more news click here

Mito Connect Call
22 November 2018

Hobart Support Group
24 November 2018

Aussiemit 2018
29 November – 1 December 2018

For more events click here

EXPERT REACTION: Senate report on allowing ‘three person IVF’ to prevent mitochondrial disease
Read about expert reactions to the Senate Report on mitochondrial donation.

Stealth Raises $100M to Advance Elamipretide as Treatment for Mitochondrial Diseases
Further development of Elamipretide as treatment for Leber’s hereditary optic neuropathy (LHON), mitochondrial myopathy, Barth syndrome, and age-related macular degeneration.

FDA Grants NeuroVive’s KL1333 Orphan Drug Status for Treatment of Mitochondrial Diseases
Orphan Drug Designation of compound KL1333 is a positive step towards bringing such treatment to patients of inherited mitochondrial respiratory chain diseases in the US.

For more media click here